Chemoimmunotherapy combined with consolidative thoracic radiotherapy for extensive-stage small cell lung cancer: A systematic review and meta-analysis

Extensive-stage small cell lung cancer (ES-SCLC) has an extremely poor prognosis, and platinum –etoposide chemotherapy has been the standard first-line treatment for over three decades[1]. Despite the initial response, relapse is frequent, and the median overall survival (OS) is merely 10 months. Recently, significant breakthroughs have been achieved in immunotherapy research for ES-SCLC. T he IMpower133 study provided compelling evidence that the addition of atezolizumab (PD-L1 inhibitor) to chemotherapy as a first-line treatment for ES-SCLC led to a substantial improvement in OS and progression-free survival (PFS)[2].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research